Drug intelligence / Profile preview

BDR-166

Development stage: Preclinical
Lead developer: MDimune
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

BDR-166 is an investigational drug in preclinical development for the treatment of neoplasms (cancers). It utilizes a novel approach combining mRNA and exosome-based modalities. The drug was initially developed by MDimune and is being further advanced by Kainos Medicine. Its mechanism of action, specific molecular targets, and detailed pharmacology have not been publicly disclosed as of the latest available information. The primary therapeutic area under investigation is oncology, with active indications in neoplasms[1][10].

Targets

FAF1 (Fas associated factor 1)

Beyond the preview

Go deeper on BDR-166.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDR-166.

Explore the full profile